LabRoots is excited to announce our 9th Annual Genetics Virtual Week held on April 20-22, 2021!
Genetics Virtual Week 2021 will offer a multi-day content-rich program combining stellar expertise from world-renowned keynote and featured speakers in the areas of Genetics & Genomics an expanding field of biology and human health, Molecular Diagnostics, exploring best laboratory practices and novel diagnostic applications, and Precision Medicine, spanning innovative technologies and solutions transforming healthcare and changing how patients are treated today.
Over the three days, invited lectures, thought-provoking discussions, and posters will be presented by academia and industry experts, professionals in medical and clinical genetics, scientific leaders, and research scholars.
This year's Genetics Virtual Week includes the following tracks:
Genetics and Genomics
Advancements in Genomic Technologies
Sex, Epigenetics, Aging, and Disease
New Approaches in the Genetics of Disease
Emerging Technologies and Methodologies in Molecular Diagnostics
Liquid Biopsies (Cancer Monitoring and Screening)
Infectious Disease Diagnostics - COVID-19 Testing
Therapeutics in Precision Medicine
Precision Medicine in Clinical Practice
The Role of Technology in Precision Medicine
Our virtual conference allows you to participate in a global setting with no travel or cost to you. The event will remain open for 2 years from the date of the live event, and the webinars will be available for unlimited on-demand viewing. This virtual conference also offers increased reach for the global microbiology community with a high degree of interaction through live-streaming video and chat sessions.
Enjoy the interactive environment via live-streaming video and chat sessions with peers, and using the Leaderboard and Gamification to move around the entire event, earning points for a chance to win one of LabRoots most popular t-shirts.
Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary and discuss results with interested colleagues through email. Plan now to have your poster included in the 2021 Genetics Virtual Week. Submit your free abstract here.
Continuing Education – LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 50 credits. This event will also provide CEU's for Genetic Counselors and is pending approval by the NSGC.
Use #LRgenetics to follow the conversation!
Suzie Alarcon CGMBS, MB(ASCP)CM is the manager of the Next Generation Sequencing Core at the La Jolla Institute for Immunology (LJI) and Team Leader of Team LJI - winner of the XPRIZE Rapid COVID Testing competition. Suzie has 18 years of experience working in molecular biology in taste, nutrition metabolomics, prenatal clinical diagnostics, epigenetics, and immunology. Her current work focuses on driving research endeavors of collaborators across the US and applies her varied experience to advise on technical development and optimization of NGS upstream workflows. She received her BS in Biology from Ursinus College, PA, US and her clinical training at Sequenom, CA, US.
Mr. Allen has over 30 years of experience in the fields of bioinformatics and software development. He is currently Director, Bioinformatics at Illumina, Inc and is the software lead for several cloud based analysis products supporting oncology, genetic disease, and microbiology related studies using whole genome sequencing, targeted sequencing, RNASeq, bisulfite sequencing, and/or metagenomics types of library preps. Most recently, he has led the teams for several COVID related data analysis products. Prior to Illumina, Mr. Allen also worked in a variety of software and data analysis roles for companies such as IBM, AT&T, Oracle, and Neurocrine Biosciences. Mr. Allen received his degrees from the University of Michigan in Ann Arbor, MI, the University of Texas in Austin, TX, and the University of San Diego in La Jolla, CA.
Orchid Allicock is a postdoctoral research associate at Yale School of Public Health with Drs. Nathan Grubaugh and Daniel Weinberger. Previously she received postdoctoral training at the Mailman School of Public Health, Columbia University, where she gained an interest in translational science and diagnostic development. Currently she works on development and optimization of saliva-based diagnostics with SalivaDirect.
Arthur P. Arnold (AB, Grinnell College; PhD, The Rockefeller University) studies mechanisms causing sex differences in physiology and disease. His research has included the discovery of large structural sexual dimorphisms in the CNS, development of several animal models for studying sex differences, and studies of mechanisms by which sex-biasing factors operate, including sex chromosome effects. Dr. Arnold is Distinguished Research Professor in the Department of Integrative Biology & Physiology at UCLA, and a fellow of the AAAS and the John Simon Guggenheim Memorial Foundation. Previous positions include departmental Chair, Associate Director of the UCLA Brain Research Institute, Chair of the UCLA interdepartmental PhD and undergraduate programs for neuroscience, founding President of the Society of Behavioral Neuroendocrinology, and founding Editor-in-Chief of Biology of Sex Differences.
Dr. Lisa Barrow-Laing has over 15 year of experience in the areas of oncology, rare disease and virology. Currently, Dr. Barrow-Laing serves as a Scientific Liaison frequently delivering workshops, trainings and product demonstrations on QIAGEN's bioinformatics offerings to oncologists, molecular pathologists, genetic counselors and other lab personnel. She assists customers with identifying the best secondary and tertiary analysis solutions to support various tests, including hereditary cancer panel and clinical exome testing. Prior to joining QIAGEN, Dr. Barrow-Laing was a Biomedical Informatics Scientist at Illumina and led clinical guideline curation projects for the Genomics England 100,000 Genome Project and clinical trial curation efforts for the ASCO TAPUR Study to identify biomarkers associated with drug sensitivity and drug resistance. She also interpreted variants and generated patient reports for pediatric patients with rare disease and cancer patients at the Illumina Clinical laboratory and N-of-One, respectively . She pursued her post-doctoral training at Brigham and Women's Hospital/Harvard Medical School and earned her Ph.D. at The Indiana University School of Medicine.
Dr. Shawn Bauer is the Director of Content Engineering at QIAGEN Digital Insights (QDI) and is responsible for scientific and bioinformatic content modeling and processing within QDI which support QIAGEN Digital Insight – Interpret (QCI-I), OmicSoftSuite, and Ingenuity Pathway Analysis (IPA). Prior to joining QIAGEN Dr. Bauer worked in drug discovery as Director of Medicinal Chemistry at Portola Pharmaceuticals where he worked on a variety of small molecule drug targets, the most recent of which led to the discovery of cerdulatinib which is currently in clinical development for leukemia and lymphoma. Dr. Bauer earned his Ph.D. in Organic Chemistry from University of California, Los Angeles.
Tracy Bedrosian leads a laboratory in the Institute for Genomic Medicine at Nationwide Children's Hospital. Her group uses single-cell sequencing approaches to understand how brain somatic mutations contribute to neurodevelopmental disorders, including developmental brain malformations, epilepsy, and autism. She also serves as an Assistant Professor of Pediatrics at The Ohio State University.
Dr. Bickhart is a Research Microbiologist/Bioinformatician at the US Department of Agriculture's Dairy Forage Research Center, where his work focuses on genome assembly of livestock species and their associated microbiomes. He has 10 years of experience in the field of Bioinformatics and Genome Informatics, and applies new technologies and algorithms to solve problems in agricultural production systems. Dr. Bickhart has been a contributor or team leader for many of the recently released reference genomes for agricultural species. The goal of this research is to improve the sustainability of agricultural systems by enabling predictive modeling of animal production with the inclusion of animal and microbial genomic information.
Dr. Matthew Forman is Head of Bioinformatics & Software at Yourgene Health, an international molecular diagnostics group which develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.
Dr. Forman joined Yourgene Health in 2013 and initially led the development of a complete turnkey solution to NGS data analysis and clinical reporting for NIPT, developed according to stringent IVD software process standards. He and his team have substantial experience of the end-to-end development of bioinformatic, biomedical and technical software systems. This begins with the design of novel bioinformatic data processing algorithms applying statistical modelling and machine learning techniques, and then manages the medical device software development lifecycle through to integration and formal testing of software modules, and finally to validation and regulatory approval of complete IVD software products.
Dr. Forman has held senior positions in research and commercial development of algorithms and software systems for medical visualisation, ultrasound and electrical impedance tomography at De Montfort University, Create3D and WZVI Ltd, developing a thorough appreciation of the statistical nature of real world genetic and biomedical data together with practical knowledge of software development methods, hardware, operating system and laboratory systems integration. He holds a B.Eng (hons) in Electronic Engineering and a Ph.D in the field of three-dimensional image processing and compression.
Greg Cooper, PhD, is a faculty investigator at the HudsonAlpha Institute for Biotechnology. Throughout his career, Cooper has focused on understanding the structures, functions and evolutionary histories of human genomes and finding ways to translate that understanding into useful predictions about human health and disease. Cooper earned a PhD in genetics from Stanford University in 2006. He completed postdoctoral research at the University of Washington in 2009 before joining HudsonAlpha in 2010.
Mara has over 15 years of experience working in the fields of microbiome, fungal genetics and bacterial diversity. As a Senior Staff Associate at Columbia University, she conducted research on diverse human microbiome projects employing next-generation sequencing techniques. This research provided greater insight into the role of the microbiome in health and disease; including stillbirth, HIV, bacterial vaginosis, colorectal cancer and maternal antibiotic exposure during pregnancy. Currently, Mara is the Director of Research & Development at Biotia, a NYC-based startup focusing on clinical diagnostics and surveillance by leveraging genomics and AI for precision infectious disease insights. Mara holds a master's degree in Fungal Genetics from the University of Georgia along with a master's degree in Microbiology from the University of Puerto Rico-Mayagüez, where she also earned her BS in Biology.
Dawn L. DeMeo, MD, MPH is a Respiratory Epidemiologist at the Channing Division of Network Medicine and a trained Pulmonary/Critical Care Physician; she is an Associate Physician in the Department of Medicine at Brigham and Women's Hospital and an Associate Professor of Medicine at Harvard Medical School. Her primary research interest is genetics and epigenetics as they relate to lung health, lung disease and intersections with sex, gender and aging. To pursue her interest in understanding COPD susceptibility, including the role of genetics and epigenetics in early-onset COPD and sex differences, she has been the recipient of grants from the National Institutes of Health, the American Lung Association and the Alpha 1 Foundation. Dr. DeMeo's vision includes streamlining effective multidisciplinary care for lung diseases through careful scientific investigations, with an eventual goal of designing and implementing genomic insights into diagnostics, therapeutics, and preventative strategies for COPD, informed by “Big Data” and Network Medicine approaches inclusive of age, sex and gender aware approaches.
Brian Dugan received his M.S. from Georgetown University in molecular biology. Previously he worked in marketing and business development positions for NGS testing, as well as research at Eunice Shriver NICHD. Brian is Associate Director for QIAGEN's UNGS Microbiomics portfolio.
Dr. Christopher Mason is an Associate Professor of Genomics, Physiology, and Biophysics at Weill Cornell Medicine and the Director of the WorldQuant Initiative for Quantitative Prediction, as well as an affiliate of Memorial Sloan Kettering Cancer Center (MSKCC), Rockefeller University, Harvard Medical School, and Yale Law School. The Mason laboratory develops and deploys new biochemical and computational methods in functional genomics to elucidate the genetic basis of human disease and physiology. We create and deploy novel techniques in next-generation sequencing and algorithms for: tumor evolution, genome evolution, DNA and RNA modifications, and genome/epigenome engineering. We also work closely with NIST/FDA to build international standards for these methods (SEQC2, IMMSA, and Epigenomics QC groups), to ensure clinical-quality genome measurements and editing. We also work with NASA to build integrated molecular portraits of genomes, epigenomes, transcriptomes, and metagenomes for astronauts, which help establish the molecular foundations and genetic defenses for enabling long-term human spaceflight. He has won the NIH's Transformative R01 Award, the NASA Group Achievement Award, the Pershing Square Sohn Cancer Research Alliance Young Investigator award, the Hirschl-Weill-Caulier Career Scientist Award, the Vallee Scholar Award, the CDC Honor Award for Standardization of Clinical Testing, and the WorldQuant Foundation Scholar Award. He was named as one of the "Brilliant Ten" Scientists by Popular Science, featured as a TEDMED speaker, and called "The Genius of Genetics" by 92Y. He has >200 peer-reviewed papers and scholarly works that have been featured on the covers of Nature, Science, Cell, Nature Biotechnology, Nature Microbiology, and Neuron, as well as legal briefs cited by the U.S. District Court and U.S. Supreme Court. Coverage of his work has also appeared on the covers of the Wall Street Journal, New York Times, TIME, The LA Times, and across many media (ABC, NBC, CBS, Fox, CNN, PBS, NASA, NatGeo). He is an inventor on four patents, co-founded five biotechnology start-up companies, and serves as an advisor to many others.
Holly Ellis completed her undergraduate degree in Biological Sciences at Oxford University and then went on to complete an MSc in Medical Genetics at Chester University. She gained another MSc in Clinical Sciences (Genomics) as part of the NHS Scientist Training Programme and she now work as a HCPC Registered Clinical Scientist in Genomics at North West Genomic Laboratory Hub (Liverpool). Holly has developed her own YouTube channel and social media platforms as "The Scouse Scientist" to inspire the next generation of scientists and raise awareness of the importance of genomics in the NHS.
Carina Emery earned a BS in biochemistry from the University of Florida and an MS in life sciences from Northwestern University. At Northwestern she used a variety of mouse models to study the molecular basis of genetic disorders affecting the nervous system. The San Diego resident then spent time in the Core Genomics facility at the University of Illinois at Chicago, where she developed a passion for utilizing the latest genomic technologies to advance research. Carina moved onto becoming a Field Applications Scientist for Bio-Rad Laboratories, supporting their digital PCR and single-cell sequencing systems. Providing technical assistance to a wide variety of researchers afforded her the firsthand knowledge that no matter how advanced your molecular analysis technology, it doesn't necessarily compensate for poor quality starting material. These days, as Product Manager for Sample Preparation at Miltenyi Biotec, the dedicated biotech professional focuses on finding solutions to ensure researchers begin their experiments armed with the best possible materials.
I lead the development of the COSMIC database (https://cancer.sanger.ac.uk), which describes millions of somatic mutations across every form of human cancer. Combining genetic research experience in Immunology at Cambridge University and Oncology at Imperial College London with Computer Science at Manchester University, I have an in-depth understanding of how genetic variants impact human phenotypes, and the knowledge of how to deploy bioinformatic solutions in precision medicine. We started COSMIC over 20 years ago as the explosion in recorded cancer genes was only just beginning; we focused on modelling both genotypic and phenotypic annotations at high resolution and this has proved essential to our broad usefulness. Ever since, our expert postdoctoral curators have been gathering ever-greater quantities of data across every mechanism of mutation that drives cancer. By ensuring resolution and precision of this information, described using the best most accessible standards, COSMIC is now a key global resource in precision oncology.
Dr. Jonathan Göke is a group leader at the Genome Institute of Singapore. Jonathan's research focuses on computational transcriptomics with a particular interest in third generation RNA-Sequencing and computational methods development. He received his PhD in Computational Biology from the Max Planck Institute for Molecular Genetics in Berlin (Germany). His team has contributed to the Pan-Cancer-Analysis-of-Whole-Genomes consortium (PCAWG) and won the DREAM challenge to predict high risk Multiple Myeloma patients. You can find out more about his research, team, and methods under http://www.jglab.org and https://github.com/GoekeLab
Donald has worked in a variety of disciplines related to the field of molecular research. He began his research career in Biomedical Engineering at Mississippi State University and later in Neuroscience studying Autism Spectrum Disorders at the University of Mississippi Medical Center. Over the past eleven years, he has worked in the research industry for well-established life sciences organizations in several roles, including, Field Engineering Specialist, Field Application Specialist, and Clinical Application Specialist. Along his varied path he has gained experience in clinical diagnostics, lab developed tests, and helping develop start-ups focused on Next Generation Sequencing (NGS) using targeted sequencing for Oncology. He continues to use his knowledge to help get new and older labs up and running with new assays or projects. Whether it is contributing to a new kit or instrument development, he enjoys working through the process. Donald values assisting biotech companies and labs find solutions for problems as they grow and adapt to the continuously changing tech landscape. For him watching them get to the next level is one of the most rewarding aspects of his job. If you were to peek at his personality profile, you would see his core skill set is what you call an integrator, meaning he specializes in bringing multifaceted teams together to drive goals to completion. What Donald genuinely wants above all else is to help labs kickstart and achieve their goals allowing them to continue to use science to make it a safer and healthier world.
Co-founder of Vizgen, Jiang He completed his postdoc at MIT in Dr. Sangeeta Bhatia's lab, and Ph.D. at Harvard University in Dr. Xiaowei Zhuang's lab. He has extensive experience in developing single molecule imaging techniques and applying them to study different biological questions, including neuroscience, cancer biology, infectious disease. Jiang has been recognized with numerous awards including Forbes 30 under 30 in Healthcare, Spotlight Scholar at AIF, and STAT Wunderkind awardee.
Nathan studies biology and graduated from The University of Alabama in Huntsville in 2014. He quickly entered the workforce handling the logistics of biological samples at Lifesouth Community Blood Centers (2014) and Conversant Bio (2017). Nathan then began serving as a feasibility associate and was responsible for evaluating all prospective customer projects. He currently serves as the Product Manager for Biospecimens and CellServices at Discovery Life Sciences.
Kyle Hondorp earned her Bachelor of Science in Genetics at the University of California, Davis. She spent 18 years working for Active Motif, a life sciences company focused on providing solutions for epigenetic research, where she held roles in R&D, manufacturing, technical support and product management. In 2008, she earned her Master of Business Administration at California State University, San Marcos. Kyle joined Thermo Fisher Scientific in 2018 and is currently a Sr. Manager, Product Management for the Applied Biosystems™ PCR plastics and thermal cycler portfolios. Kyle is dedicated to providing PCR workflow solutions.
Dr Horvath's research lies at the intersection of aging research, epidemiology, chronic diseases, epigenetics, genetics, and systems biology. He works on all aspects of biomarker development with a particular focus on genomic biomarkers of aging. He developed a highly accurate multi-tissue biomarker of aging known as the epigenetic clock. Dr Horvath developed systems biologic approaches such as weighted gene co-expression network analysis which lend themselves for integrating gene genomic data sets. These methods have been used for a broad spectrum of age related diseases including neurodegenerative diseases, cancer, cardiovascular disease. Dr. Horvath received a Ph.D. in Mathematics from the University of North Carolina, Chapel Hill in 1995 and a Doctorate of Science in Biostatistics from the Harvard School of Public Health in 2000.
Nicole received her Ph.D. in Microbiology from the University of California, Riverside where gained extensive research experience in viral immunology. Nicole is also a ASCP board certified Specialist in Cytometry and leads the development of our genomic cell sorting applications.
Dr. Dominic John is the VP of Clinical Product Management and Marketing at QIAGEN. Dominic is responsible for overseeing the QIAGEN Digital Insights marketing programs and Clinical Products that have been used in genomic profiling of over 2M patient cases worldwide for oncology and hereditary disease diagnosis. Dominic has spent over 20 years researching, developing and delivering leading cheminformatics and bioinformatics software to push the boundaries of science from bench to bedside applications. Driven by scientific curiosity, Dominic brings a range of experience from lab informatics, automation, simulation, data science and clinical decision support software. Dominic possesses a master in Toxicology, Ph.D. in Biochemistry and a carried out a Post Doctorate in Genomics.
Dr. Hertz is an assistant professor in the Department of Clinical Pharmacy at the University of Michigan College of Pharmacy. Dr. Hertz received his PharmD from Rutgers University and PhD from UNC for his dissertation research on pharmacogenetic predictors of taxane-induced neuropathy. Dr. Hertz's current research is interested in developing tools for individualizing treatment in patients with cancer and translating them into clinical practice. He has a particular interest in optimal use of paclitaxel for women with breast cancer, including identification of an ideal exposure target to maximize efficacy while avoiding unnecessary toxicity. Dr. Hertz has several other ongoing projects to discover and translate genetic variants that affect cancer treatment outcomes, in collaborations with medical oncologists at the University of Michigan Rogel Cancer Center and within SWOG.
Dr Howard McLeod is an internationally recognized expert in precision medicine, having made novel contributions at the discovery, translation, implementation, and policy levels. He is the Medical Director for Precision Medicine at the Geriatric Oncology Consortium and a Professor at the University of South Florida Taneja College of Pharmacy. Dr McLeod chaired the NHGRI eMERGE network external scientific panel for the past decade and was a recent member of both the FDA committee on Clinical Pharmacology and the NIH Human Genome Advisory Council. Dr McLeod has been recognized as a Fellow of both the American Society of Clinical Oncology and the American College of Clinical Pharmacy and was recently ranked #1 USA/#2 World for Pharmacogenomics. He has also been an active Board Member and/or Founder for over a dozen privately held and publicly traded companies. Howard has published over 575 peer reviewed papers on pharmacogenomics, applied therapeutics, or clinical pharmacology and continues to work to advance innovative healthcare.